761373-05-1(2S,4R)-Sacubitril
● In Stock
| Catalogue No.: | VE009208 |
|---|---|
| CAS No.: | 761373-05-1 |
| Mol. Formula: | C24H29NO5 |
| Mol. Weight: | 411.49 g/mol |
Additional information on CAS 761373-05-1
Parent drug
SacubitrilIUPAC Name
(4-(((2R,4S)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid)Pharmacopoeial Synonyms
N/AOther synonyms
[R-(R*, S*)]-γ-[(3-Carboxy-1-oxopropyl)amino]-α-methyl-[1, 1′-biphenyl]-4-pentanoic Acid α-Ethyl EsterSmiles
O=C(O)CCC(N[C@H](C[C@H](C)C(OCC)=O)CC1=CC=C(C2=CC=CC=C2)C=C1)=OInChI
InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m0/s1Description
(2S,4R)-Sacubitril (CAS 761373-05-1) is the stereodefined active pharmaceutical ingredient framework of sacubitril, with molecular formula C24H29NO5 and molecular weight 411.49 g/mol. In impurity profiling, this compound is evaluated as a process-related stereoisomeric material or as a specification marker for enantiomeric and diastereomeric control during synthesis and resolution. Its amide-containing prodrug architecture and hydrophobic aromatic ester moieties favor reversed-phase LC separation, while chiral LC, LC-MS/MS, and high-resolution MS are typically required for definitive assignment. Regulatory assessment may consider stereochemical purity, interconversion risk, and trace-level occurrence arising from incomplete asymmetric synthesis or resolution inefficiency.References
Nicolas, Diala, et al. “Sacubitril/Valsartan.†Nih.gov, StatPearls Publishing, 9 May 2022, www.ncbi.nlm.nih.gov/books/NBK507904/. ‌Request a Quote
"*" indicates required fields
![(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate](https://veeprho.com/wp-content/uploads/2023/11/VE0016600-2R-4S-ethyl-5-1-1-biphenyl-4-yl-4-amino-2-methylpentanoate.png)





![(R,E)-5-([1,1-Biphenyl]-4-Yl)-4-((Tert-Butoxycarbonyl)Amino)-2-Methylpent-2-Enoic Acid (R,E)-5-([1,1-Biphenyl]-4-Yl)-4-((Tert-Butoxycarbonyl)Amino)-2-Methylpent-2-Enoic Acid](https://veeprho.com/wp-content/uploads/2024/05/R-E-5-1-1-Biphenyl-4-Yl-4-Tert-Butoxycarbonyl-Amino-2-Methylpent-2-Enoic-Acid.png)

![(2S,4R)-5-([1,1'-Biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic Acid (2S,4R)-5-([1,1'-Biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic Acid](https://veeprho.com/wp-content/uploads/2023/03/2S-4R-5-1-1-Biphenyl-4-yl-4-tert-butoxycarbonyl-amino-2-methylpentanoic-Acid.png)
![(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic Acid (2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic Acid](https://veeprho.com/wp-content/uploads/2026/02/2R4S-5-Biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic-Acid-1012341-50-2-VE009680-ac14.png)